Suppr超能文献

亲脂性对多粘菌素衍生物抗菌活性及其作为利福平增效剂能力的影响。

Influence of Lipophilicity on the Antibacterial Activity of Polymyxin Derivatives and on Their Ability to Act as Potentiators of Rifampicin.

作者信息

Brown Pamela, Abdulle Omar, Boakes Steven, Divall Naomi, Duperchy Esther, Ganeshwaran Sonia, Lester Roy, Moss Stephen, Rivers Dean, Simonovic Mona, Singh Jaspal, Stanway Steven, Wilson Antoinette, Dawson Michael J

机构信息

Cantab Anti-Infectives Ltd., BioPark, Broadwater Road, Welwyn Garden City AL7 3AX, United Kingdom.

Spero Therapeutics Inc., 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts 02139, United States.

出版信息

ACS Infect Dis. 2021 Apr 9;7(4):894-905. doi: 10.1021/acsinfecdis.0c00917. Epub 2021 Mar 10.

Abstract

Novel polymyxin derivatives are often classified either as having direct activity against Gram-negative pathogens or as compounds inactive in their own right, which through permeabilization of the outer membrane act as potentiators of other antibiotics. Here, we report the systematic investigation of the influence of lipophilicity on microbiological activity (including against strains with reduced susceptibility to polymyxins), potentiation of rifampicin, and toxicity within a series of next-generation polymyxin nonapeptides. We demonstrate that the lipophilicity at the N-terminus and amino acids 6 and 7 in the cyclic peptide core is interchangeable and that the activity, ability to potentiate, and cytotoxicity all appear to be primarily driven by overall lipophilicity. Our work also suggests that the characterization of a polymyxin molecule as either a direct acting compound or a potentiator is more of a continuum that is strongly influenced by lipophilicity rather than as a result of fundamentally different modes-of-action.

摘要

新型多粘菌素衍生物通常被分类为要么对革兰氏阴性病原体具有直接活性,要么本身无活性,但其通过使外膜通透化而充当其他抗生素的增效剂。在此,我们报告了对一系列下一代多粘菌素九肽中亲脂性对微生物活性(包括对多粘菌素敏感性降低的菌株)、利福平增效作用及毒性影响的系统研究。我们证明,环肽核心中N端以及第6和7位氨基酸的亲脂性是可互换的,且活性、增效能力和细胞毒性似乎均主要由整体亲脂性驱动。我们的研究还表明,将多粘菌素分子表征为直接作用化合物或增效剂更像是一个受亲脂性强烈影响的连续体,而非源于根本不同的作用模式。

相似文献

3
Design of Next Generation Polymyxins with Lower Toxicity: The Discovery of SPR206.
ACS Infect Dis. 2019 Oct 11;5(10):1645-1656. doi: 10.1021/acsinfecdis.9b00217. Epub 2019 Sep 24.
5
Development of dilipid polymyxins: Investigation on the effect of hydrophobicity through its fatty acyl component.
Bioorg Chem. 2018 Oct;80:639-648. doi: 10.1016/j.bioorg.2018.07.018. Epub 2018 Jul 19.
8
Enhancing the antibacterial activity of polymyxins using a nonantibiotic drug.
Infect Drug Resist. 2019 May 27;12:1393-1405. doi: 10.2147/IDR.S196874. eCollection 2019.
9
Dilipid Ultrashort Tetrabasic Peptidomimetics Potentiate Novobiocin and Rifampicin Against Multidrug-Resistant Gram-Negative Bacteria.
ACS Infect Dis. 2020 Jun 12;6(6):1413-1426. doi: 10.1021/acsinfecdis.0c00017. Epub 2020 May 7.
10
Inhibition of the ATP Synthase Eliminates the Intrinsic Resistance of towards Polymyxins.
mBio. 2017 Sep 5;8(5):e01114-17. doi: 10.1128/mBio.01114-17.

引用本文的文献

1
Total Synthesis of Kavaratamides A-C and Unnatural Analogs.
ACS Omega. 2025 Jun 13;10(24):26052-26060. doi: 10.1021/acsomega.5c02929. eCollection 2025 Jun 24.
3
Unnatural Amino Acids: Strategies, Designs, and Applications in Medicinal Chemistry and Drug Discovery.
J Med Chem. 2024 Nov 28;67(22):19932-19965. doi: 10.1021/acs.jmedchem.4c00110. Epub 2024 Nov 11.
4
Molecular guidelines for promising antimicrobial agents.
Sci Rep. 2024 Feb 26;14(1):4641. doi: 10.1038/s41598-024-55418-6.
7
Polymyxins with Potent Antibacterial Activity against Colistin-Resistant Pathogens: Fine-Tuning Hydrophobicity with Unnatural Amino Acids.
J Med Chem. 2024 Jan 25;67(2):1370-1383. doi: 10.1021/acs.jmedchem.3c01908. Epub 2024 Jan 3.
9
Atomic-Resolution Structures and Mode of Action of Clinically Relevant Antimicrobial Peptides.
Int J Mol Sci. 2022 Apr 20;23(9):4558. doi: 10.3390/ijms23094558.

本文引用的文献

1
Direct modifications of the cyclic peptide Polymyxin B leading to analogues with enhanced in vitro antibacterial activity.
Bioorg Med Chem Lett. 2020 Jun 1;30(11):127163. doi: 10.1016/j.bmcl.2020.127163. Epub 2020 Mar 30.
2
Plastic binding feature of polymyxins: the effect on MIC susceptibility measurements.
Infect Drug Resist. 2019 Aug 27;12:2649-2653. doi: 10.2147/IDR.S219130. eCollection 2019.
3
Potentiation of Antibiotics against Gram-Negative Bacteria by Polymyxin B Analogue SPR741 from Unique Perturbation of the Outer Membrane.
ACS Infect Dis. 2020 Jun 12;6(6):1405-1412. doi: 10.1021/acsinfecdis.9b00159. Epub 2019 Oct 23.
4
Design of Next Generation Polymyxins with Lower Toxicity: The Discovery of SPR206.
ACS Infect Dis. 2019 Oct 11;5(10):1645-1656. doi: 10.1021/acsinfecdis.9b00217. Epub 2019 Sep 24.
5
Discovery of Novel Polymyxin-Like Antibiotics.
Adv Exp Med Biol. 2019;1145:343-362. doi: 10.1007/978-3-030-16373-0_20.
6
Mechanisms of Polymyxin Resistance.
Adv Exp Med Biol. 2019;1145:55-71. doi: 10.1007/978-3-030-16373-0_5.
8
The "Old" and the "New" Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How.
Front Public Health. 2019 Jun 11;7:151. doi: 10.3389/fpubh.2019.00151. eCollection 2019.
9
Polymyxin Derivatives that Sensitize Gram-Negative Bacteria to Other Antibiotics.
Molecules. 2019 Jan 11;24(2):249. doi: 10.3390/molecules24020249.
10
β-lactam/β-lactamase inhibitor combinations: an update.
Medchemcomm. 2018 Aug 17;9(9):1439-1456. doi: 10.1039/c8md00342d. eCollection 2018 Sep 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验